Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy

Annals of Internal Medicine

Volumn 133, Issue 6, 2000, Pages

  Grabar, S ^a   Le Moing, V ^a   Goujard, C ^a   Leport, C ^a   Kazatchkine, M D ^a   Costagliola, D ^a   Weiss, L ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; FRANCE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINASE INHIBITION; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS GENE;

EID: 0034687071     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-6-200009190-00007     Document Type: Article

References (33)

1. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
3. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
4. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
5. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
6. + lymphocytes as prognostic markers of HIV-1 infection
7. + lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team
8. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS
9. The relative prognostic value of plasma HRNA levels and CD4 lymphocyte counts in advanced HIV infection
10. + cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine
11. CD4 cell counts at the third month of HAART may predict clinical failure
12. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
13. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy
14. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART) [Letter]. Swiss HIV Cohort Study
15. + cell counts despite persistendy detectable HIV load
16. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
17. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
18. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
19. Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study Group
20. Clinical progression and virological failure on highly active anti-retroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
21. + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy
22. Immune reconstitution, T ceil proliferation and discordant responses on HAART
23. Incomplete IL-2 response but restoration of T-cell reactivity to CMV antigens in patients exhibiting discordant immunological and virological responses under HAART
24. 3 despite effective HAART
25. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
26. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure
27. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo
28. T-cell turnover kinetics in patients with sustained CD4 cell response after experiencing virologic failure of a protease inhibitor-based regimen
29. + T cells and decreases their susceptibility to apoptosis in vitro and in vivo
30. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study
31. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group
32. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
33. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel